PropThink’s Week in the Life Sciences
Most Popular - Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Here Are the Reasons to Own Keryx, and Why Key Catalysts are De-Risked
Long Ideas - Following PropThink’s conference call with Dr. Scott Chambers on Thursday, we’re quite comfortable with the short-term and long-term patent protection on Zerenex, Keryx’s (KERX) novel … Continue Reading
Read nowBioLife Solutions: Long-Term Potential is Intact as Growth Continues
Long Ideas - For many investors, the notion of investing in an OTC stock is difficult to grasp. Such stocks are often illiquid and volatile, however, painting with … Continue Reading
Read nowData from the Closest Competition, It Turns Out, Support Sarepta
Long Ideas - Data from the Closest Competition, It Turns Out, Support Sarepta Accelerated approval aside, the chatter regarding Sarepta Therapeutics (SRPT) in the past week has centered … Continue Reading
Read nowUnilife’s Syringe Commercialization Agreement is a Sign of Progress
Long Ideas - On April 9, Unilife (UNIS) announced that it had inked a long-term commercial supply agreement with a U.S. pharmaceutical company related to the company’s EZMix syringe platform. … Continue Reading
Read nowWhat You Need to Know About Keryx and Zerenex’s IP – A PropThink Expert Call
Long Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read nowWhere We’re Finding Value for Biotech Investors
Most Popular - PropThink kicked off the week by revisiting Endo Health (ENDP) and brought the scoop on Rajiv De Silva’s materializing plans for the company. De Silva, … Continue Reading
Read now